ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

Frequency and Abundance of ALK/ROS1/MET Mutations on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer Using Single Molecule Amplifcation and Re-sequencing Technology: a Perspective Observational Study

The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC

Inclusion Criteria:

• Histologically confirmed stage IIIB/IV NSCLC;
• Histologically confirmed adenocarcinoma;
• EGFR-wildtype NSCLC;
• Provision of blood (plasma) sample for ctDNA testing;
• Patient must be able to comply with the protocol;
• Provision of blood (plasma) sample for ctDNA testing;

Exclusion Criteria:

• As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease);
• Histologically confirmed small cell lung cancer or other metastatic tumors;
• Patient with no histologic or cytological diagnosis;